NYSE:PEN Penumbra Q4 2025 Earnings Results & Report $319.28 +1.76 (+0.55%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$319.40 +0.12 (+0.04%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Penumbra missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released February 25, 2026. The company reported EPS of -$0.37 versus the $1.12 consensus estimate, while revenue of $385.39 million topped the $367.18 million estimate by $18.21 million. Revenue increased 22.2% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 25, 2026TimeBefore Market OpensConference Call1:00 PM ET Penumbra EPS ResultsActual EPS-$0.37Consensus EPS $1.12Beat/MissMissed by -$1.49One Year Ago EPS$0.97EPS Beat Rate5 of last 8 quartersPenumbra Revenue ResultsActual Revenue$385.39 millionExpected Revenue$367.18 millionBeat/MissBeat by +$18.21 millionYoY Revenue Growth+22.20%Upcoming EarningsPenumbra's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Penumbra Q4 2025 Earnings FAQ Did Penumbra beat earnings estimates for Q4 2025? Penumbra (NYSE:PEN) reported earnings of -$0.37 per share for Q4 2025, missing the consensus estimate of $1.12. The report was announced on Wednesday, February 25, 2026. What was Penumbra's revenue for Q4 2025? Penumbra reported revenue of $385.39 million for Q4 2025, against a consensus estimate of $367.18 million. When is Penumbra's next earnings date? Penumbra's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Penumbra on the company's earnings history page. Penumbra Earnings HeadlinesPenumbra, Inc. (NYSE:PEN) Stock Has Consensus Target Price of $367.07 According to AnalystsOctober 9 at 2:29 AM | americanbankingnews.comRBC Capital Keeps Their Hold Rating on Penumbra (PEN)October 8 at 7:49 PM | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 11 at 1:00 AM | Base Camp Trading (Ad)Penumbra (PEN) Clinical Data Puts Its Valuation Back In FocusOctober 8 at 7:49 PM | finance.yahoo.comPenumbra, Inc. Announces Results from A Subset Analysis of the Landmark STORM-PE Randomized Controlled TrialOctober 7, 2026 | marketscreener.comMNew STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary EmbolismOctober 6, 2026 | prnewswire.comSee More Penumbra Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email. Email Address About PenumbraPenumbra (NYSE:PEN) is a medical device company that develops, manufactures and markets products used to treat vascular conditions and other serious medical disorders. The company is best known for its minimally invasive technologies designed to remove blood clots, restore blood flow and support the treatment of neurovascular conditions, including ischemic stroke. Its product portfolio includes aspiration and thrombectomy systems, embolization devices, access and delivery systems, and other technologies used by physicians in neurointerventional and peripheral vascular procedures. Penumbra also develops products for treating aneurysms, arteriovenous malformations and selected conditions affecting blood vessels outside the brain. Founded in 2004 and headquartered in Alameda, California, Penumbra serves hospitals and health care providers in the United States and international markets. The company’s products are distributed through a combination of direct sales and international distribution arrangements. Adam Elsesser is Penumbra’s chairman and chief executive officer.View Penumbra ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
